Product Description
Mechanisms of Action: Imaging Agent,Radioactive Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Czech | Denmark | Finland | France | Germany | Greece | Netherlands | Norway | Slovenia | Sweden | Switzerland
Approved Indications: None
Known Adverse Events: None
Company: Medical University of Vienna
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-519348-34-00 | P2 |
Unknown Status |
Prostate Cancer |
2025-10-01 |